Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract #1855: The novel Hsp90 inhibitor NVP-AUY922 reduces insulin-like growth factor receptor type 1 expression and lowers migration rate in triple-negative breast cancer cells

Paul Berghuis, Carolina Schröder, Hetty Timmer-Bosscha, Michael Jensen, Cornelia Quadt, Steven de Jong and Elisabeth de Vries
Paul Berghuis
University Medical Centre Groningen, Groningen, Netherlands; Novartis Institutes for BioMedical Research, Basel, Switzerland; Novartis Pharma AG, Basel, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina Schröder
University Medical Centre Groningen, Groningen, Netherlands; Novartis Institutes for BioMedical Research, Basel, Switzerland; Novartis Pharma AG, Basel, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hetty Timmer-Bosscha
University Medical Centre Groningen, Groningen, Netherlands; Novartis Institutes for BioMedical Research, Basel, Switzerland; Novartis Pharma AG, Basel, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Jensen
University Medical Centre Groningen, Groningen, Netherlands; Novartis Institutes for BioMedical Research, Basel, Switzerland; Novartis Pharma AG, Basel, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cornelia Quadt
University Medical Centre Groningen, Groningen, Netherlands; Novartis Institutes for BioMedical Research, Basel, Switzerland; Novartis Pharma AG, Basel, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven de Jong
University Medical Centre Groningen, Groningen, Netherlands; Novartis Institutes for BioMedical Research, Basel, Switzerland; Novartis Pharma AG, Basel, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth de Vries
University Medical Centre Groningen, Groningen, Netherlands; Novartis Institutes for BioMedical Research, Basel, Switzerland; Novartis Pharma AG, Basel, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

Breast cancer is the leading cause of cancer death among women worldwide. Triple negative breast cancer (negative for estrogen-, progesterone and human epidermal growth factor receptor 2 -HER2-) is a subgroup comprising 12.5% of the patients, which have a more aggressive phenotype with a tendency for early dissemination and onset at an early age. Overexpression of IGF-1R, a transmembrane receptor tyrosine kinase involved in tumor cell motility and metastatic spread, has been associated with increased malignancy degree of numerous solid tumors including breast cancer. The large majority of triple negative breast cancers (70-80%) express IGF-1R, and this is associated with a worse prognosis. Heat shock protein 90 (HSP90) is a key component of a multichaperone complex involved in post-translational folding of several oncogenic client proteins, including IGF-1R. Disrupting IGF-1R signalling by means of HSP90 inhibition is therefore potentially of interest for treating triple negative breast cancer. The most studied HSP90 inhibitor is 17AAG. However, due to its relatively poor physiochemical properties, there is a need for HSP90 inhibitors with better pharmaceutical characteristics. In this study we explore whether the novel HSP90 inhibitor NVP-AUY922 reduces IGF-1R expression and hampers IGF-1 mediated migration in triple negative breast cancer. MDA-MB-231 cells were exposed to increasing concentrations of NVP-AUY922 (0-500 nM) and compared with 17-AAG (0-500 nM) and were analysed for IGF-1R expression by Western-blotting, flow-cytometry and immunohistochemistry. The effects on IGF-1 induced migration were established by wound-healing assays. ER-positive MCF-7 cells were used as reference model. IGF-1R expression was strongly decreased (23% compared to control) after NVP-AUY922 (200nM) treatment, whereas 17-AAG (500nM) had no effect on IGF-1R levels in MDA-MB-231 cells. Both 17-AAG and NVP-AUY922 were effective in MCF-7 cells. Immunofluorescent labelling revealed the localization of IGF-1R to actin-rich regions in the leading edge of migrating breast cancer cells, with a reduced staining intensity after NVP-AUY922 treatment. IGF-1 stimulated migration rate in both MDA-MB-231 (157%) and MCF-7 (212%) cells. In accordance with the effects of HSP90 inhibition on IGF-1R expression, NVP-AUY922 (50nM) reduced IGF-1 stimulated migration (61% compared to IGF-1 stimulated cells). 17-AAG did not affect migration of MDA-MB-231 cells. In this study we have shown that HSP90 inhibition by the novel compound NVP-AUY922 potently reduces the membrane expression levels of IGF-1R and affects IGF-1 induced migration in triple negative breast cancer cells. HSP90 inhibition could be a significant systemic treatment option for triple negative breast cancer patients via inhibition of the IGF-1R pathway.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1855.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #1855: The novel Hsp90 inhibitor NVP-AUY922 reduces insulin-like growth factor receptor type 1 expression and lowers migration rate in triple-negative breast cancer cells
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #1855: The novel Hsp90 inhibitor NVP-AUY922 reduces insulin-like growth factor receptor type 1 expression and lowers migration rate in triple-negative breast cancer cells
Paul Berghuis, Carolina Schröder, Hetty Timmer-Bosscha, Michael Jensen, Cornelia Quadt, Steven de Jong and Elisabeth de Vries
Cancer Res May 1 2009 (69) (9 Supplement) 1855;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #1855: The novel Hsp90 inhibitor NVP-AUY922 reduces insulin-like growth factor receptor type 1 expression and lowers migration rate in triple-negative breast cancer cells
Paul Berghuis, Carolina Schröder, Hetty Timmer-Bosscha, Michael Jensen, Cornelia Quadt, Steven de Jong and Elisabeth de Vries
Cancer Res May 1 2009 (69) (9 Supplement) 1855;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Protein Kinase and Other Inhibitors in Mechanism-Based Drug Cytotoxicity -- Poster Presentations - Proffered Abstracts

  • Abstract #1857: The novel HSP90 inhibitor, PU-H71, synergizes with cisplatin and blocks invasion and migration of ovarian cell lines.
  • Abstract #1833: The in vitro and in vivo anti-tumor effect of KO-202125, a sauristolactam derivative, as a novel EGFR inhibitor in human breast cancer
  • Abstract #1848: Effect of the protein Farnesyltransferase expression on HDAC6 activity and cellular sensitivity to taxane treatment
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement